ImportantAgreements
Gujarat Themis Biosyn (GTBL) is acquiring 100% of Japan's MicroBiopharm Japan (MBJ) for ~INR 1,300 Cr.
Gujarat Themis Biosyn LimitedGUJTHEM · Filed with the exchange
MBJ, a pharma CDMO with ~INR 570 Cr FY26E revenue, enhances GTBL's strategy to become a tech-driven CDMO in precision fermentation and biotechnology.
No comments yet. Be the first.